New CAR T-Cell therapy aims to control Hard-to-Treat multiple myeloma
NCT ID NCT07421856
First seen Feb 19, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This early-stage study tests a new treatment called S103 for people with multiple myeloma that has returned or stopped responding to standard therapies. S103 uses a patient's own immune cells, modified to target and attack the cancer. The main goals are to check safety and find the best dose, with 24 participants expected to take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.